







SL-89. DRD2 inhibitors

Dopamine GPCR receptors are predominant in the central nervous system (CNS), and participate in various neurological processes. Several recent studies demonstrated that dopamine receptors D2 are also associated with tumorigenesis [1,2]. Some antipsychotic drugs showed anti-neoplastic effects on human cancers as adjuvants

enhancing the efficacy of anticancer therapy in breast and colon cancer cell lines [3,4]

A pharmacophore search through ASINEX's compound collection identified several molecules that can be explored for GPCR research and anticancer drug discovery.

		
AAM 10789997	ADM 11107725	AEM 09584111
		
AEM 10837957	AEM 12673968	AOP 12854845

Signature Library 89

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 µmol; 1 µmol DMSO solutions	SL#89_DRD2_inh.sdf

References:

1. *Cell*. 2012 Jun 8;149(6):1284-97. doi: 10.1016/j.cell.2012.03.049
2. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1633-8.
3. *Oncol Lett*. 2016 Feb;11(2):1281-1286. doi: 10.3892/ol.2016.4074
4. *Neoplasia*. 2018 Jan; 20(1): 80–91. doi: 10.1016/j.neo.2017.10.002

Contact us:

USA: +1 336 721 1617
Japan: +81-80-3401-9097
Europe/Global:

asinex@asinex.com
sota@asinex.com
lsadovenko@asinex.com

